Lexington, Mass.-based Homology Medicines launched today with a $43.5 million Series A preferred stock financing.
Homology Medicines will focus on a new gene editing technology, which the founders claim are a better version of CRISPR-Cas9. None of the company’s work has been published, although one of the company’s investors indicates it will publish findings soon.
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
Lexington, Mass.-based Homology Medicines launched today with a $43.5 million Series A preferred stock financing.
Homology Medicines will focus on a new gene editing technology, which the founders claim are a better version of CRISPR-Cas9. None of the company’s work has been published, although one of the company’s investors indicates it will publish findings soon.